As filed with the Securities
and Exchange Commission on May 14, 2020
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CYREN
LTD.
(Exact
name of registrant as specified in its charter)
|
Israel
|
|
Not
applicable
|
(State
or other jurisdiction
of incorporation or organization)
|
|
(I.R.S.
Employer
Identification Number)
|
10
Ha-Menofim St., 5th Floor
Herzliya,
Israel, 4672561
011–972–9–863–6888
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Eric
Spindel
General
Counsel
Cyren
Ltd.
c/o
Cyren Inc.
1430
Spring Hill Road, Suite 330
McLean,
Virginia 22102
(703)
760-3320
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Laurie
L. Green, Esq.
Greenberg
Traurig, P.A.
401
East Las Olas Boulevard, Suite 2000
Fort
Lauderdale, Florida 33301
(954)
768-8232
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration
Statement.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box. ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans,
check the following box. þ
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.
☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer ☐
Non-accelerated
filer þ
|
|
Accelerated
filer ☐
Smaller
reporting company þ
Emerging
growth company ☐
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION
OF REGISTRATION FEE
|
Title of Each Class of Securities to be Registered
|
|
Amount to be
Registered(1)
|
|
|
Proposed
Maximum
Offering
Price per
Share(2)
|
|
|
Proposed
Maximum
Aggregate
Offering
Price(2)
|
|
|
Amount of
Registration
Fee
|
|
|
Ordinary Shares, par value ILS 0.15 per share
|
|
|
16,586,396
|
|
|
$
|
0.94
|
|
|
$
|
15,591,212.24
|
|
|
$
|
2,023.74
|
|
|
(1)
|
We
are registering 16,586,396 ordinary shares (i) issuable upon conversion of $10,250,002 aggregate principal amount of outstanding
5.75% Convertible Debentures due 2024, or the Debentures, which were issued to the selling shareholders named in the prospectus
included in this registration statement in a private placement, and (ii) issuable to the selling shareholders as interest
payable pursuant to the terms of the Debentures. All of the shares being registered hereby are offered for the account of
the selling shareholders upon conversion of the Debentures held by such selling shareholders and receipt by such selling shareholders
of additional shares issuable as interest payable under the Debentures. Pursuant to Rule 416 under the Securities Act, this
registration statement shall also cover an indeterminate number of additional ordinary shares that may become issuable by
virtue of any dividend, stock split, recapitalization or other similar transaction.
|
|
(2)
|
Estimated
solely for the purposes of calculating the registration fee. Pursuant to Rule 457(c) under the Securities Act, the registration
fee has been calculated based upon the average of the high and low prices, as reported by the Nasdaq Capital Market, for our
ordinary shares on May 11, 2020.
|
The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
Information
in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
DATED
MAY 14, 2020, SUBJECT TO COMPLETION
PRELIMINARY
PROSPECTUS
Cyren
Ltd.
16,586,396
Ordinary Shares
This
prospectus relates to the proposed resale from time to time of up to 16,586,396 ordinary shares, par value ILS 0.15 per share,
by the selling shareholders named herein, together with any additional selling shareholders listed in a prospectus supplement
(together with any of such shareholders’ pledgees, assignees, and successors-in-interest).
The
shares to be sold hereunder are issuable by us (i) upon conversion of outstanding 5.75% Convertible Debentures due 2024, or the
Debentures, held by the selling shareholders, and (ii) as interest payable pursuant to the terms of the Debentures. We are registering
the offer and sale of the ordinary shares issuable to the selling shareholders under the Debentures to satisfy the registration
rights they were granted in connection with the issuance of the Debentures. We will not receive any proceeds from the sale of
the ordinary shares by the selling shareholders.
The
selling shareholders may offer and sell or otherwise dispose of the ordinary shares described in this prospectus from time to
time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately
negotiated prices. The selling shareholders will bear all underwriting fees, commissions and discounts, if any, attributable to
the sales of shares and any transfer taxes. We will bear all other costs, expenses and fees in connection with the registration
of the shares. See “Plan of Distribution” for more information about how the selling shareholders may sell or dispose
of their ordinary shares.
Our
ordinary shares are listed on the Nasdaq Capital Market under the trading symbol “CYRN.” On May 13, 2020, the closing
price for our ordinary shares was $0.99 per share.
Investing
in these securities involves certain risks. See “Risk Factors” on page 2 of this prospectus. Also see “Risk
Factors” in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully
consider before deciding to purchase these securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is _______, 2020
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC,
using a “shelf” registration process. Under this shelf process, certain selling shareholders may from time to time
sell the ordinary shares described in this prospectus in one or more offerings or otherwise as described under “Plan of
Distribution.”
This
prospectus may be supplemented from time to time by one or more prospectus supplements. Such prospectus supplement may also add,
update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus
and the applicable prospectus supplement, you must rely on the information in the prospectus supplement. You should carefully
read both this prospectus and any applicable prospectus supplement together with additional information described under the heading
“Where You Can Find More Information” before deciding to invest in any ordinary shares being offered.
Neither
we nor the selling shareholders have authorized anyone to provide any information other than that contained or incorporated by
reference in this prospectus or in any related prospectus supplement or any free writing prospectus that we have authorized. We
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. The shares are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information
contained in or incorporated by reference in this prospectus is accurate as of any date other than the respective dates of such
document. Our business, financial condition, results of operations and prospects may have changed since those dates.
Unless
the context otherwise indicates, references in this prospectus to “we,” “our,” “us” and “Cyren”
refer, collectively, to Cyren Ltd., an Israeli registered public company, and its subsidiaries.
PROSPECTUS SUMMARY
THE COMPANY
Purpose built for the cloud, we are an early
pioneer and leading innovator of Software-as-a-Service, or SaaS, security solutions that protect businesses, their employees and
customers against threats from email and the web.
Our cloud-based approach to security sets
us apart from other vendors in the market. Our security solutions are architected around the fundamental belief that cybersecurity
is a race against time – and the cloud best enables the speed, sophistication and advanced automation needed to detect and
block threats as they emerge on the internet. As more and more businesses move their data and applications to the cloud, they need
a security provider that is able to keep pace.
Our cloud security products and services
fall into three categories:
|
|
●
|
Cyren
Threat Detection Services – these services detect a variety of threats in email and from the web, and are embedded
into products from the world’s leading technology and security vendors. Cyren Threat Detection Services include our Email
Security Detection Engine, Malware Detection Engine, Web Security Engine, and Threat Analysis Service.
|
|
|
●
|
Cyren
Threat Intelligence Feeds – Cyren’s threat intelligence feeds provide valuable threat intelligence data that
can be used by enterprise or OEM customers to support threat detection, threat hunting and incident response. Cyren’s threat
intelligence feed offerings include IP Reputation Intelligence, Phishing Intelligence, Malware Intelligence and Zombie Intelligence.
|
|
|
●
|
Cyren
Enterprise Email Security Products – these include cloud-based solutions designed for enterprise customers, and
are sold either directly or through channel partners. Cyren enterprise email security products include Cyren Email Security, a
cloud-based secure email gateway and Cyren Inbox Security, an anti-phishing product for Office 365.
|
We were incorporated as a private company
under the laws of the State of Israel on February 10, 1991 and our legal form is a company limited by shares. We became a public
company on July 15, 1999 under the name Commtouch Software Ltd. In January 2014, we changed our legal name to Cyren Ltd. Our website
is https://www.cyren.com. The SEC maintains an internet site that contains reports, proxy and information statements and other
information regarding issuers that file electronically with the SEC. Our filings under the Exchange Act are available on our website
and are also available electronically from the website maintained by the SEC at www.sec.gov.
Our principal executive offices are located
at 10 Ha-Menofim St., 5th Floor, Herzliya, Israel 4672561, where our telephone number is +972–9–863–6888.
RISK
FACTORS
Investing
in our securities involves a high degree of risk. Please carefully consider the following factors as well as the other information
contained and incorporated by reference in this prospectus, including the risk factors set forth under the caption “Item
1A. Risk Factors” in our most recent Annual Report on Form 10-K, as well as any amendments thereto reflected in subsequent
filings with the SEC. Before making an investment decision, you should carefully consider these risks as well as other information
we include or incorporate by reference in this prospectus.
Your
investment may be significantly diluted by the conversion of our Debentures and the payment of interest in ordinary shares.
A
substantial number of ordinary shares could be issued upon conversion of our Debentures and issued as interest on the Debentures.
Sales of substantial amounts of our ordinary shares in the public market, or the possibility of these sales, may adversely affect
our stock price. As of May 11, 2020, 16,586,396 ordinary shares were reserved for issuance upon conversion of the $10,250,000
principal amount of outstanding Debentures (including shares issuable in respect of 5.75% interest payable if the Debentures are
held until maturity). If issued, the shares underlying our Debentures would increase the number of ordinary shares currently outstanding
and will dilute the holdings and voting rights of our then-existing shareholders. Further, if we elect to issue ordinary shares
as payment of interest under the Debentures, the actual number of ordinary shares issued will be based on fluctuating trading
prices of our ordinary shares prior to the interest payment date. To the extent that the price of our ordinary shares declines,
and we elect to issue ordinary shares as payment of interest under the Debentures, we will need to issue more ordinary shares
to satisfy the interest payment, which will result in further dilution.
Adjustments
to the conversion price for our Debentures issued to the Selling Shareholders will further dilute the ownership interests of our
existing shareholders.
Our
Debentures are convertible at any time after issuance, in whole or in part, at the holder’s option, into ordinary shares
at a fixed conversion price equal to $0.75 per share. The fixed conversion price contains a “full-ratchet” anti-dilution
provision which provides that if we issue ordinary shares or ordinary share equivalents at a price less than the current conversion
price at any time during the 12 month period following the issuance date, the conversion price of the Debentures will be automatically
reduced to such lower price. However, the reduced conversion price for the Debentures held by Brett Jackson, our Chief Executive
Officer, cannot be less than $0.73.
Any
reduction in the conversion price below the initial fixed conversion price of $0.75 will result in additional shares being issued
upon conversion of the Debentures, including amounts converted in respect of interest, that would further dilute our existing
shareholders.
We
are currently not in compliance with the Nasdaq Capital Market listing standards. If our ordinary shares are delisted,
the market price and liquidity of our ordinary shares and our ability to raise additional capital would be adversely impacted.
Our
ordinary shares are currently listed on the Nasdaq Capital Market. Continued listing of a security on the Nasdaq Capital Market
is conditioned upon compliance with various continued listing standards. On April 24, 2020, we received written notice, or
the Notice, from the Listing Qualifications Department of the Nasdaq Stock Market informing us that because the closing bid price
for our ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days prior to
the date of the Notice, we do not currently meet the minimum closing bid requirement for continued listing on the Nasdaq Capital
Market set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. We have until December
28, 2020 to regain compliance.
In
the event that our ordinary shares are not eligible for continued listing on the Nasdaq Capital Market or another national securities
exchange, trading of our ordinary shares could be conducted in the over-the-counter market or on an electronic bulletin board
established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult
to dispose of, or obtain accurate price quotations for, our ordinary shares, and there would likely also be a reduction in our
coverage by security analysts and the news media, which could cause the price of our ordinary shares to decline further. Also,
it may be difficult for us to raise additional capital if we are not listed on a major exchange.
Where
you can find more information
This
prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain
all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts,
agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration
statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such
contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act,
we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available
to the public over the Internet at the SEC’s website at http://www.sec.gov.
You
may also access our SEC filings at our website http://www.cyren.com. Our website is not a part of this prospectus and is not incorporated
by reference in this prospectus.
INCORPORATION
BY REFERENCE
The
SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference into
this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the
SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included
or incorporated into this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference
to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified
or superseded. This prospectus incorporates by reference the documents listed below (File No. 000-26495):
We
incorporate by reference into this prospectus the information contained in the following documents, which is considered to be
a part of this prospectus:
|
|
●
|
the Annual Report on Form 10-K for the year ended December 31, 2019;
|
|
|
|
|
|
|
●
|
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020;
|
|
|
|
|
|
|
●
|
the Current Reports on Form 8-K filed with the SEC on March 17, 2020, March 19, 2020, and April 30, 2020; and
|
|
|
|
|
|
|
●
|
the description of our ordinary shares contained in our Form 8-A filed on June 25, 1999 and Form F-1 (File No. 333-78531) filed on May 14, 1999, as amended, as updated by Exhibit 4.1 to the Annual Report on Form 10-K for the year ended December 31, 2019 and any reports filed for the purpose of updating such description.
|
We
also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K
and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with
the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial
filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement,
until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus,
which will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future
filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed
to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier
statements. You may obtain a copy of these filings, without charge, by writing or calling us at:
1430
Spring Hill Road, Suite 330
McLean, Virginia 22102
Attn: Investor Relations
Telephone Number (703) 760-3320
FORWARD-LOOKING
STATEMENTS
This
prospectus and the information incorporated by reference in this prospectus include “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act.
These statements are based on current expectations, estimates, forecasts and projections about the industry in which we operate
and the beliefs and assumptions of our management. In addition, statements in the future tense, and statements including words
such as “anticipate,” “believe,” “expect,” “plan,” “intend,” “estimate,”
and similar expressions are intended to identify forward-looking statements. Specifically, this prospectus and the information
incorporated by reference in this prospectus contain forward-looking statements regarding:
|
|
●
|
our intention to release two new enterprise-focused product offerings in 2020 and the anticipated solutions such offerings will provide to our customers;
|
|
|
●
|
our expectations regarding the timing of availability of our CIS solution to the market and the timing of its revenue impact;
|
|
|
●
|
our expectations regarding our integrated offering and our partnership with Microsoft;
|
|
|
|
|
|
|
●
|
our expectations that our utilization of our cloud infrastructure will increase and provide opportunity for improved gross margins;
|
|
|
●
|
our
expectations regarding our future profitability and revenue growth;
|
|
|
●
|
our expectations regarding increases in cost of revenue and operating expenses, including as a result of our anticipated investments in R&D;
|
|
|
●
|
our
expectations that R&D expenses may decrease as we release new products during 2020 and that G&A expenses will continue
to grow in absolute dollars as we continue our operational growth;
|
|
|
●
|
our
beliefs regarding the importance of R&D;
|
|
|
●
|
our
expectation to lower the rate of R&D investment as a percentage of revenue in the future and to drive more revenue from existing
solutions rather than by adding new solutions;
|
|
|
●
|
our
expectations regarding reducing the historical rate of headcount growth and its resulting impact on our gross and operating margins
over time;
|
|
|
●
|
our
expectations regarding our business strategies, including our contingency plan;
|
|
|
●
|
our
expectations regarding growth of our enterprise business and its expected impact on our business, including its contribution to
our cash flow and return on investment;
|
|
|
●
|
our
expectations regarding our capital expenditures for 2020;
|
|
|
●
|
our
belief regarding the adequacy of our existing capital resources and other future measures to satisfy our expected liquidity requirements;
|
|
|
●
|
our beliefs regarding our competitive position in the market in which we operate;
|
|
|
●
|
our expectations regarding the regulatory environment of data privacy in the EU;
|
|
|
●
|
our anticipated significant investments in R&D and promotion of our brand;
|
|
|
●
|
our
expectations regarding trends in the market for internet security and technology industry;
|
|
|
●
|
our
expectations regarding existing and new threats, key challenges and opportunities in our industry and their impact on our business,
including the impact of innovations in the technology industry;
|
|
|
●
|
our
expectations regarding the increase in utilization of our cloud infrastructure and the resulting impact on our gross margins;
|
|
|
●
|
our
expectations regarding continued and future customers that will contribute to our revenue, and the solutions we provide to such
customers;
|
|
|
●
|
our
beliefs regarding factors that make our vision compelling to the IT security market;
|
|
|
●
|
our
expectations regarding the locations where we conduct our business;
|
|
|
●
|
our
belief regarding passive foreign investment company status;
|
|
|
●
|
our
expectations regarding the impact of litigation;
|
|
|
●
|
our
beliefs regarding our net operating loss carry-forwards; and
|
|
|
●
|
our
expectations and estimates regarding certain tax and accounting matters, including the impact on our financial statements.
|
These
forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions.
We wish to caution readers that certain important factors may have affected and could in the future affect our actual results
and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important
factors that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the
actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not
limited to, the following:
|
|
●
|
our
ability to execute our business strategies, including our sales and business development plan;
|
|
|
●
|
our
ability to timely and successfully enhance and improve our existing solutions and introduce our new solutions;
|
|
|
●
|
the
commercial success of such enhancements and new solutions;
|
|
|
●
|
lack
of demand for our solutions, including as a result of actual or perceived decreases in levels of advanced cyber attacks;
|
|
|
●
|
our
ability to manage our cost structure, avoid unanticipated liabilities and achieve profitability;
|
|
|
●
|
our
ability to grow our revenues, including the ability of existing solutions to drive sufficient revenue;
|
|
|
●
|
our
ability to attract new customers and increase revenue from existing customers;
|
|
|
●
|
market
acceptance of our existing and new product offerings;
|
|
|
●
|
the
success of our partnership with Microsoft, including our ability to successfully integrate our web security technology into its
platform;
|
|
|
●
|
our
ability to adapt to changing technological requirements and shifting preferences of our customers and their users;
|
|
|
●
|
the
impact of the of the COVID-19 outbreak;
|
|
|
●
|
our
continued listing on Nasdaq;
|
|
|
●
|
our
ability to successfully shift the focus of our product development and sales efforts to new products, while de-emphasizing our
CWS offerings;
|
|
|
●
|
loss
of any of our large customers;
|
|
|
●
|
adverse
conditions in the national and global financial markets;
|
|
|
●
|
the
impact of currency fluctuations;
|
|
|
●
|
political
and other conditions in Israel that may limit our R&D activities;
|
|
|
●
|
increased
competition or our ability to anticipate or effectively react to competitive challenges;
|
|
|
●
|
the
ability of our brand development strategies to enhance our brand recognition;
|
|
|
●
|
our
ability to retain key personnel;
|
|
|
●
|
performance
of our OEM partners, service providers and resellers;
|
|
|
●
|
our
ability to successfully implement our contingency plan, if needed, and its ability to allow us to continue our operations and
meet our cash obligations;
|
|
|
●
|
our
ability to successfully estimate the impact of regulatory and litigation matters;
|
|
|
●
|
our
ability to comply with applicable laws and regulations and the impact of changes in applicable laws and regulations, including
tax legislation or policies;
|
|
|
●
|
economic,
regulatory and political risks associated with our international operations;
|
|
|
●
|
the
impact of cyber attacks or a security breach of our systems;
|
|
|
●
|
our
ability to protect our brand name and intellectual property rights;
|
|
|
●
|
the
impact of our controlling shareholder’s decisions, which may differ with respect to our strategic direction;
|
|
|
●
|
our
ability to successfully estimate the impact of certain accounting and tax matters, including the effect on our company of adopting
certain accounting pronouncements; and
|
|
|
●
|
those
risks detailed in the section of this prospectus entitled “Risk Factors,” and those risks described in the documents
we file from time to time with the SEC that are incorporated by reference in this prospectus, specifically our most recent Annual
Report on Form 10-K, Form 10-Q and our Current Reports on Form 8-K.
|
Except
as required by applicable law, including the securities laws of the United States, we undertake no obligation to update or revise
any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof.
ENFORCEABILITY
OF CIVIL LIABILITIES
We
are organized under the laws of the State of Israel, and many of our directors and executive officers, as well as the Israeli
experts named herein are not residents of the United States, and substantially all of their assets and our assets are located
outside the United States. Service of process upon our non-U.S. resident directors and executive officers or the Israeli experts
named herein and enforcement of judgments obtained in the United States against us, our directors and executive officers, or the
Israeli experts named herein, may be difficult to obtain within the United States. For further information regarding enforceability
of civil liabilities against us and certain other persons, see the risk factor “You may have difficulties enforcing a U.S.
judgment against us and our executive officers and directors or asserting U.S. securities laws claims in Israel” under the
heading “Risk Factors” in our most recent Annual Report on Form 10-K, which is incorporated by reference herein.
Cyren
Inc. is the U.S. agent authorized to receive service of process in any action against us arising out of this offering or any related
purchase or sale of securities. We have not given consent for this agent to accept service of process in connection with any other
claim.
USE
OF PROCEEDS
We
will not receive any proceeds from the sale of any or all of the ordinary shares being offered by the selling shareholders under
this prospectus.
SELLING
SHAREHOLDERS
The
ordinary shares being offered by the selling shareholders are those issuable to the selling shareholders, upon conversion of the
Debentures. We are registering the ordinary shares in order to permit the selling shareholders to offer up to 16,586,396 ordinary
shares for resale from time to time. The selling shareholders may acquire such ordinary shares upon the conversion of, and as
interest payments on, the $10.25 million aggregate principal amount of our outstanding Debentures held by selling shareholders
and originally issued pursuant to the Securities Purchase Agreements, dated March 17, 2020, by and among the selling shareholders
and us. The Debentures were originally issued in a private placement exempt from the registration requirements of the Securities
Act, by virtue of Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Under the terms of the Debentures, subject
to certain exceptions, interest on the outstanding principal amount is payable semi-annually, in cash or, at the Company’s
option, in ordinary shares using a conversion rate based on the trailing 10-trading day volume weighted average price, or VWAP,
of our ordinary shares on the trading day that is three trading days prior to the applicable interest payment date.
Except
for the ownership of the ordinary shares and the Debentures, the selling shareholders, other than Brett Jackson, our Chief Executive
Officer, have not had any material relationship with us within the past three years.
The
following table sets forth (i) the name of each selling shareholder, (ii) the number of shares beneficially owned by each of the
respective selling shareholders, (iii) the number of ordinary shares that may be offered under this prospectus, and (iv) the number
of ordinary shares owned by the selling shareholders assuming all of the ordinary shares covered hereby are sold. The “Percentage
of Ordinary Shares Beneficially Owned After Offering” is based on 59,972,055 ordinary shares outstanding as of April 30,
2020. The selling shareholders may sell all, some or none of their shares in this offering. The
information presented regarding the selling shareholders is based, in part, on information the selling shareholders provided to
us in writing specifically for use in this prospectus.
The
information in the column, “Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus,” assumes the
sale of shares issuable upon full conversion of the Debentures and as interest payable on the Debentures if held until maturity.
The
actual number of ordinary shares issuable upon conversion of the Debentures is subject to adjustment upon certain corporate events
such as stock splits and if we issue ordinary shares or ordinary share equivalents at a price less than the current conversion
price at any time during the 12 month period following the issuance date. In addition, the actual number of ordinary shares issued
as payment of interest under the Debentures is based on fluctuating trading prices of our ordinary shares. Further, pursuant to
the terms of the Debentures, a selling shareholder may not exercise the Debentures to the extent such exercise would cause such
selling shareholder, together with its affiliates and attribution parties, to beneficially own a number of ordinary shares which
would exceed 4.99% of our then outstanding ordinary shares following such exercise, excluding for purposes of such determination
ordinary shares issuable upon conversion of the debentures which have not been exercised. The number of shares set forth in the
following table for any selling shareholder does not take into account this limitation. Accordingly, the number of ordinary shares
set forth in the following table for any shareholder may exceed the number of ordinary shares that it could beneficially own at
any given time as a result of its ownership of the Debentures. As a result, the actual number of ordinary shares that may be issued
to and sold by the selling shareholders could be materially less or more than the estimated numbers in the column titled “Maximum
Number of Ordinary Shares to be Sold Pursuant to this Prospectus” depending on factors which cannot be predicted at this
time. In addition, we do not know how long the selling shareholders will hold the ordinary shares before selling them, and we
currently have no agreements, arrangements or understandings with the selling shareholders regarding the sale or other disposition
of any ordinary shares.
Except
as otherwise noted herein, the number and percentage of ordinary shares beneficially owned is determined in accordance with Rule 13d-3
of the Exchange Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under
such rule, beneficial ownership includes any ordinary shares as to which the individual has sole or shared voting power or investment
power and also any ordinary shares which the individual has the right to acquire within 60 days of the date of this prospectus
through the exercise of any option or other right. Unless otherwise indicated in the footnotes, each person has sole
voting and investment power with respect to the ordinary shares shown as beneficially owned.
|
Name of Selling Shareholder
|
|
Number of Ordinary Shares Beneficially Owned Prior to Offering
|
|
|
Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus
|
|
|
Number of Ordinary Shares Beneficially Owned After Offering
|
|
|
Percentage of Ordinary Shares Beneficially Owned After Offering
|
|
|
Brett M. Jackson, Chief Executive Officer
|
|
|
850,834
|
(1)
|
|
|
404,547
|
|
|
|
517,500
|
|
|
|
*
|
|
|
Blackwell Partners LLC - Series A
|
|
|
1,353,800
|
(2)(3)
|
|
|
1,643,023
|
|
|
|
-
|
|
|
|
-
|
|
|
Herald Investment Management Limited for and on behalf of Herald Investment Trust plc
|
|
|
1,333,334
|
(4)
|
|
|
1,618,185
|
|
|
|
-
|
|
|
|
-
|
|
|
Inductive Capital LP
|
|
|
600,000
|
(5)
|
|
|
728,183
|
|
|
|
-
|
|
|
|
-
|
|
|
Lytton-Kambara Foundation
|
|
|
1,745,580
|
(6)
|
|
|
1,618,185
|
|
|
|
412,246
|
|
|
|
*
|
|
|
Manatuck Hill Mariner Master Fund, LP
|
|
|
237,334
|
(7)
|
|
|
288,038
|
|
|
|
-
|
|
|
|
-
|
|
|
Manatuck Hill Navigator Master Fund, LP
|
|
|
190,667
|
(8)
|
|
|
231,401
|
|
|
|
-
|
|
|
|
-
|
|
|
Manatuck Hill Scout Fund, LP
|
|
|
572,000
|
(9)
|
|
|
694,201
|
|
|
|
-
|
|
|
|
-
|
|
|
MAZ Partners LP
|
|
|
133,334
|
(10)
|
|
|
161,820
|
|
|
|
-
|
|
|
|
-
|
|
|
Nantahala Capital Partners II Limited Partnership
|
|
|
1,726,532
|
(11)(3)
|
|
|
2,095,385
|
|
|
|
-
|
|
|
|
-
|
|
|
Nantahala Capital Partners Limited Partnership
|
|
|
634,428
|
(12)(3)
|
|
|
769,966
|
|
|
|
-
|
|
|
|
-
|
|
|
NCP QR LP
|
|
|
703,352
|
(13)(3)
|
|
|
853,615
|
|
|
|
-
|
|
|
|
-
|
|
|
Nantahala Capital Partners SI, LP
|
|
|
4,515,224
|
(14)(3)
|
|
|
5,479,847
|
|
|
|
-
|
|
|
|
-
|
|
*Less than 1%.
|
(1)
|
Consists of (i) 315,000 ordinary shares issuable upon the exercise
of options that are exercisable within 60 days, (ii) 202,500 ordinary shares underlying restricted stock units vesting on July
30, 2020, and (iii) 333,334 ordinary shares issuable upon conversion of the Debenture held by Mr. Jackson.
|
|
(2)
|
Consists of 1,353,800 ordinary shares issuable upon conversion of the Debenture held by such selling shareholder.
|
|
|
|
|
(3)
|
Nantahala Capital Management, LLC is a registered investment adviser and has been delegated the legal power to vote and/or direct the disposition of such securities on behalf of such selling shareholder as a general partner or investment manager and would be considered the beneficial owner of such securities. The above shall not be deemed to be an admission by the record owners or such selling shareholder that they are themselves beneficial owners of these securities for purposes of Section 13(d) of the Exchange Act or any other purpose. Wilmot Harkey and Daniel Mack are managing members of Nantahala Capital Management, LLC and may be deemed to have voting and dispositive power over the ordinary shares held by the selling shareholder.
|
|
|
|
|
(4)
|
Consists of 1,333,334 ordinary shares issuable upon conversion of the Debenture held by Herald Investment Management Limited for and on behalf of Herald Investment Trust plc. Katherine Potts, Fraser Elms and Taymour Ezzat have voting and dispositive power over the securities beneficially held by such selling shareholder.
|
|
|
|
|
(5)
|
Consists of 600,000 ordinary shares issuable upon conversion of the Debenture held by Inductive Capital LP. William Burnham has voting and dispositive power over the securities beneficially held by such selling shareholder.
|
|
|
|
|
(6)
|
Consists of (i) 412,246 ordinary shares and (ii) 1,333,334 ordinary shares issuable upon conversion of the Debenture held by Lytton-Kambara Foundation. Laurence Lytton has voting and dispositive power over the securities beneficially owned by such selling shareholder.
|
|
|
|
|
(7)
|
Consists of 237,334 ordinary shares issuable upon conversion of the Debenture held by Manatuck Hill Mariner Master Fund, LP. Mark Broach has voting and investment power over the securities beneficially owned by such selling shareholder. Mr. Broach may be deemed to share beneficial ownership of the securities beneficially owned by such selling shareholder.
|
|
|
|
|
(8)
|
Consists of 190,667 ordinary shares issuable upon conversion of the Debenture held by Manatuck Hill Navigator Master Fund, LP. Mark Broach has voting and investment power over the securities beneficially owned by such selling shareholder. Mr. Broach may be deemed to share beneficial ownership of the securities beneficially owned by such selling shareholder.
|
|
|
|
|
(9)
|
Consists of 572,000 ordinary shares issuable upon conversion of the Debentures held Manatuck Hill Scout Fund, LP. Mark Broach has voting and investment control over the securities beneficially owned by such selling shareholder. Mr. Broach may be deemed to share beneficial ownership of the securities beneficially owned by such selling shareholder.
|
|
|
|
|
(10)
|
Consists of 133,334 ordinary shares issuable upon conversion of the Debenture held by MAZ Partners LP. Walter Schenker is a principal of MAZ Partners LP and has voting and investment power with respect to the shares held by MAZ Partners LP.
|
|
|
|
|
(11)
|
Consists of 1,726,532 ordinary shares issuable upon conversion of the Debenture held by such selling shareholder.
|
|
|
|
|
(12)
|
Consists of 634,428 ordinary shares issuable upon conversion of the Debenture held by such selling shareholder.
|
|
|
|
|
(13)
|
Consists of 703,352 ordinary shares issuable upon conversion of the Debenture held by such selling shareholder.
|
|
|
|
|
(14)
|
Consists of 4,515,224 ordinary shares issuable upon conversion of the Debenture held by such selling shareholder.
|
PLAN
OF DISTRIBUTION
Each
selling shareholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time,
sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading
facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling
shareholder may use any one or more of the following methods when selling securities:
|
|
●
|
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
●
|
block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
as principal to facilitate the transaction;
|
|
|
●
|
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
|
●
|
an
exchange distribution in accordance with the rules of the applicable exchange;
|
|
|
●
|
privately
negotiated transactions;
|
|
|
●
|
settlement
of short sales;
|
|
|
●
|
in
transactions through broker-dealers that agree with the selling shareholders to sell a specified number of such securities at
a stipulated price per security;
|
|
|
●
|
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
|
●
|
a
combination of any such methods of sale; or
|
|
|
●
|
any
other method permitted pursuant to applicable law.
|
The
selling shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act,
if available, rather than under this prospectus.
Broker-dealers
engaged by the selling shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling shareholders (or, if any broker-dealer acts as agent for the purchaser of securities,
from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an
agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a
principal transaction a markup or markdown in compliance with FINRA IM-2440.
In
connection with the sale of the securities or interests therein, the selling shareholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of
hedging the positions they assume. The selling shareholders may also sell securities short and deliver these securities to close
out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling
shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one
or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered
by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).
The
selling shareholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling shareholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities.
The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The
Company has agreed to indemnify the selling shareholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.
We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling
shareholders pursuant to Rule 144 under the Securities Act, (ii) all of the securities have been sold pursuant to this prospectus
or Rule 144 under the Securities Act or any other rule of similar effect and March 19, 2022. The resale securities will be sold
only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain
states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.
Under
applicable rules and regulations under the Exchange Act of 1934, or the Exchange Act, any person engaged in the distribution of
the resale securities may not simultaneously engage in market making activities with respect to the ordinary shares for the applicable
restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling shareholders
will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M,
which may limit the timing of purchases and sales of the ordinary shares by the selling shareholders or any other person. We will
make copies of this prospectus available to the selling shareholders and have informed them of the need to deliver a copy of this
prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
The
validity of the ordinary shares offered hereby will be passed upon by Yigal Arnon & Co., Israel.
EXPERTS
The
consolidated financial statements of Cyren Ltd. appearing in our most recent Annual Report on Form 10-K (including schedules appearing
therein), have been audited by Kost Forer Gabbay & Kasierer (a member of EY Global), independent registered public accounting
firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial
statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in
accounting and auditing.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
ITEM
14. Other Expenses of Issuance and Distribution.
The
following table sets forth an estimate of the fees and expenses payable by us in connection with the sale of the securities being
registered.
|
SEC registration fee
|
|
$
|
2,023.74
|
|
|
Accounting fees and expenses
|
|
$
|
3,000.00
|
|
|
Legal fees and expenses
|
|
$
|
50,000.00
|
|
|
Miscellaneous fees and expenses
|
|
$
|
2,000.00
|
|
|
Total
|
|
$
|
57,023.74
|
|
ITEM
15. Indemnification of Directors and Officers.
Under
the Israeli Companies Law 1999, as amended, or the Companies Law, a company may not exculpate an office holder from liability
for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company,
in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing
such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision.
The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.
Under
the Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for
acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an
event, provided its articles of association include a provision authorizing such indemnification:
|
|
●
|
financial
liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s
award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided
in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen
based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria
determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned
foreseen events and amount or criteria;
|
|
|
●
|
reasonable
litigation expenses, including attorneys’ fees, incurred by the office holder as a result of an investigation or proceeding
instituted against him or her by an authority authorized to conduct such investigation or proceeding, (1) provided that (i) no
indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability
was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding; or (2)
provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii)
a financial liability was imposed, but it was imposed with respect to an offense that does not require proof of criminal intent
or in connection with a monetary sanction;
|
|
|
●
|
reasonable
litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings instituted
against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the
office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent;
|
|
|
●
|
payments
which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities
Law 1968, as amended, or the Securities Law, and expenses the office holder incurred in connection with a proceeding under Chapters
H’3, H’4 or I’1 of the Securities Law, including reasonable litigation expenses, including attorney’s
fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law; and
|
|
|
●
|
expenses
incurred by the office holder in connection with a proceeding under Chapter G’1 of the Restrictive Trade Law 1988, or the
Restrictive Trade Law, including reasonable litigation expenses, including attorney’s fees.
|
Under
the Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him
or her as an office holder if and to the extent provided in the company’s articles of association:
|
|
●
|
a
breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to
believe that the act would not harm the company;
|
|
|
●
|
a
breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of
the office holder;
|
|
|
●
|
a
financial liability imposed on the office holder in favor of a third party;
|
|
|
●
|
a
payment which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities
Law and expenses that the office holder incurred in connection with a proceeding under Chapters H’3, H’4 or I’1
of the Securities Law, including reasonable litigation expenses, including attorney’s fees, or in connection with Article
D of Chapter Four of Part Nine of the Companies Law; and
|
|
|
●
|
Expenses
incurred by the office holder in connection with a proceeding under Chapter G’1, of the Restrictive Trade Law, including
reasonable litigation expenses, including attorney’s fees.
|
Under
the Companies Law, a company may not indemnify or insure an office holder against any of the following:
|
|
●
|
a
breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to
the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;
|
|
|
●
|
a
breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office
holder;
|
|
|
●
|
an
act or omission committed with intent to derive illegal personal benefit; or
|
|
|
●
|
a
fine or forfeit levied against the office holder.
|
Further,
the Securities Law, prohibits companies from exempting or indemnifying in advance or entering into a contract to insure the liability
of an office holder of the company for (A) financial sanctions pursuant to the provisions of Chapter H’3 of the Securities
Law; (B) administrative infringements pursuant to the provisions of Chapter H’4 of the Securities Law or (C) infringements
pursuant to the provisions of Chapter I’1 of the Securities Law.
Under
the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by
the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances,
also by the shareholders.
The
Company’s amended and restated articles of association permit it to exculpate, indemnify and insure its office holders to
the fullest extent permitted or to be permitted by the Israeli Companies Law.
The
Company has obtained directors’ and officers’ liability insurance for the benefit of its office holders and intends
to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies
Law.
ITEM
16. Exhibits.
ITEM
17. Undertakings.
The
undersigned registrant hereby undertakes:
|
|
(a)(1)
|
To
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
|
|
|
(i)
|
to
include any prospectus required by Section 10(a)(3) of the Securities Act;
|
|
|
(ii)
|
to
reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
|
|
|
(iii)
|
to
include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement
or any material change to such information in this Registration Statement;
|
provided, however,
that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section
13 or Section 15(d) of the Exchange Act, that are incorporated by reference in this Registration Statement, or is contained in
a form of prospectus filed pursuant to Rule 424(b) that is part of this Registration Statement.
|
|
(2)
|
That,
for the purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall
be deemed to be the initial bona fide offering thereof.
|
|
|
(3)
|
To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
the termination of the offering.
|
|
|
(4)
|
That,
for the purpose of determining liability under the Securities Act to any purchaser:
|
|
|
(i)
|
each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the
date the filed prospectus was deemed part of and included in the Registration Statement; and
|
|
|
(ii)
|
each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part
of a registration statement in reliance on Rule 430B relating to an offering made pursuant
to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required
by Section 10(a) of the Securities Act shall be deemed to be part of and included in
the Registration Statement as of the earlier of the date such form of prospectus is first
used after effectiveness or the date of the first contract of sale of securities in the
offering described in the prospectus. As provided in Rule 430B, for liability purposes
of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the Registration Statement relating to the securities
in the Registration Statement to which that prospectus relates, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering
thereof; provided, however, that no statement made in a registration statement
or prospectus that is part of the Registration Statement or made in a document incorporated
or deemed incorporated by reference into the Registration Statement or prospectus that
is part of the Registration Statement will, as to a purchaser with a time of contract
of sale prior to such effective date, supersede or modify any statement that was made
in the Registration Statement or prospectus that was part of the Registration Statement
or made in any such document immediately prior to such effective date.
|
|
|
(5)
|
That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of such undersigned registrant
pursuant to this registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, such undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
|
|
|
(i)
|
any
preliminary prospectus or prospectus of such undersigned registrant relating to the offering required to be filed pursuant to
Rule 424;
|
|
|
(ii)
|
any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;
|
|
|
(iii)
|
the
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of such undersigned registrant; and
|
|
|
(iv)
|
any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
|
|
(6)
|
That,
for purposes of determining any liability under the Securities Act:
|
|
|
(i)
|
the
information omitted from the form of prospectus filed as part of the Registration Statement in reliance upon Rule 430A and contained
in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be
deemed to be part of the Registration Statement as of the time it was declared effective; and
|
|
|
(ii)
|
each
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
|
|
|
(7)
|
The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated
by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
|
|
|
|
|
|
|
(8)
|
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been
advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the city of McLean, Commonwealth of Virginia, on May 14, 2020.
|
|
CYREN LTD.
|
|
|
|
|
|
|
By:
|
/s/ Brett Jackson
|
|
|
|
Brett Jackson
|
|
|
|
Chief Executive Officer
|
SIGNATURES
AND POWER OF ATTORNEY
We,
the undersigned officers and directors of Cyren Ltd. hereby severally constitute and appoint Brett Jackson and J. Michael Myshrall,
and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for
us and in our names in the capacities indicated below the Registration Statement on Form S-3 filed herewith and any and all amendments
(including post-effective amendments) to said Registration Statement, and any registration statement filed pursuant to Rule 462
under the Securities Act of 1933, as amended, in connection with said Registration Statement, and to file or cause to be filed
the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
and generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable Cyren
Ltd. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange
Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall
do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated.
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Brett Jackson
|
|
Chief Executive Officer and Director
|
|
May 14, 2020
|
|
Brett Jackson
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/ J. Michael Myshrall
|
|
Chief Financial Officer
|
|
May 14, 2020
|
|
J. Michael Myshrall
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Lior Samuelson
|
|
Chairman
|
|
May 14, 2020
|
|
Lior Samuelson
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Todd Thomson
|
|
Director
|
|
May 14, 2020
|
|
Todd Thomson
|
|
|
|
|
|
|
|
|
|
|
|
/s/ John Becker
|
|
Director
|
|
May 14, 2020
|
|
John Becker
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Brian Chang
|
|
Director
|
|
May 14, 2020
|
|
Brian Chang
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Cary Davis
|
|
Director
|
|
May 14, 2020
|
|
Cary Davis
|
|
|
|
|
|
|
|
|
|
|
|
/s/ David Earhart
|
|
Director
|
|
May 14, 2020
|
|
David Earhart
|
|
|
|
|
|
|
|
|
|
|
|
/s/ James Hamilton
|
|
Director
|
|
May 14, 2020
|
|
James Hamilton
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Hila Karah
|
|
Director
|
|
May 14, 2020
|
|
Hila Karah
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Rajveer Kushwaha
|
|
Director
|
|
May 14, 2020
|
|
Rajveer Kushwaha
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Lauren Zletz
|
|
Director
|
|
May 14, 2020
|
|
Lauren Zletz
|
|
|
|
|
16
